| 中文名称: | SC-236 | ||||
|---|---|---|---|---|---|
| 英文名称: | SC-236 | ||||
| 别名: | 4-(5-(4-氯苯基)-3-(三氟甲基)-1H- 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide | ||||
| CAS No: | 170569-86-5 | 分子式: | C16H11ClF3N3O2S | 分子量: | 401.79 |
| CAS No: | 170569-86-5 | ||||
| 分子式: | C16H11ClF3N3O2S | ||||
| 分子量: | 401.79 | ||||
基本信息
|
产品编号： |
S10709 |
||||
|
产品名称： |
SC-236 |
||||
|
CAS: |
170569-86-5 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
分子式： |
溶于液体 |
-80℃ |
6个月 |
||
|
分子量： |
401.79 |
-20℃ |
1个月 |
||
|
化学名： |
4-[5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE |
||||
|
Solubility (25°C)： |
|||||
|
体外:
|
DMSO |
|
|||
|
Ethanol |
|
||||
|
Water |
|
||||
|
体内(现配现用): |
|
||||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
制备储备液
|
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
|
1mM |
2.4889mL |
12.4443mL |
24.8886mL |
|
5mM |
0.4978mL |
2.4889mL |
4.9777mL |
|
10mM |
0.2489mL |
1.2444mL |
2.4889mL |
生物活性
|
产品描述 |
是具有口服活性的COX-2特异性抑制剂 (对COX-1的IC50值为10nM)和PPARγ激动剂。 |
||
|
靶点 |
COX-2 10nM (IC50) |
COX-1 17.8μM (IC50) |
|
|
体外研究 |
SC-236 (15μM,30 min) suppresses the side effects of NSAIDs and prevented inflammation in vECs subjected to ALSS.SC-236 significantly induces PPARγ expression in HSCs and acted as a potent PPARγ agonist in a luciferase-reporter transactivation assay.SC-236 strongly inhibits, in a time- and concentration-dependent manner,macrophageviability.SC-236,either alone or in combination with 15d-PGJ2,induced a marked pro-apoptotic effect in HSCs in culture.SC-236 mediates antitumor effect by modulation of AP-1-signaling pathway. Western Blot Analysis |
||
|
Cell Line: |
vECs. |
||
|
Concentration: |
15μM |
||
|
Incubation Time: |
30 min. |
||
|
Result: |
Showd significant reduction in COX-2 level and increase in IκBα level,thus preventing ALSS-induced NFκB activation and inflammation in vECs. |
||
|
Western Blot Analysis |
|||
|
Cell Line: |
COS 7 cells. |
||
|
Concentration: |
3 and 10μM. |
||
|
Incubation Time: |
18h (combined with 15d-PGJ2). |
||
|
Result: |
Acted in a concentration-dependent manner as a PPARγ agonist. |
||
|
体内研究 |
SC-236 (6mg/kg,gavage) exhibits anti-fibrotic properties in CCl4- treated animals. |
||
|
Animal Model: |
Seventy-six male adult Wistar rats weighing 200-220g (CCl4-treated). |
||
|
Dosage: |
6mg/kg. |
||
|
Administration: |
Orally,3 times per week. |
||
|
Result: |
A marked induction of COX-2 protein expression was detected by immunohistochemistry in the liver of CCl4-treated rats. Significantly reduced the degree of liver fibrosis.Dramatically suppressed α-SMA expression in CCl4-treated rats. |
||
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
